Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review

References

• Haller CS, Padmanabhan JL, Lizano P, Torous J, Keshavan M. Recent advances in understanding schizophrenia. F1000Prime Rep. 2014;6:1.
   PubMedGoogle Scholar
• McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76. doi:10.1093/epirev/mxn001
   PubMed Web of Science ®Google Scholar
• Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–224. doi:10.1016/S2215-0366(18)30511-X
   PubMed Web of Science ®Google Scholar
• Harrow M, Jobe T, Faull R. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med. 2014;44(14):3007–3016. doi:10.1017/S0033291714000610
   PubMed Web of Science ®Google Scholar
• Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296–1306. doi:10.1093/schbul/sbs130
   PubMed Web of Science ®Google Scholar
• Rice DP. The economic impact of schizophrenia. J Clin Psychiatry. 1999;60(1):4–6.
   PubMedGoogle Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. doi:10.1016/S0140-6736(13)60733-3
   PubMed Web of Science ®Google Scholar
• Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205–1218. doi:10.1017/S1461145712001277
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi:10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• Ventura J, Subotnik KL, Guzik LH, et al. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res. 2011;132(1):18–23. doi:10.1016/j.schres.2011.06.025
   PubMed Web of Science ®Google Scholar
• Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1–3):393–399. doi:10.1016/j.schres.2015.08.015
   PubMed Web of Science ®Google Scholar
• Excellence NIfHaC. Psychosis and schizophrenia in adults: prevention and management; 2014.
   Google Scholar
• Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British association for psychopharmacology. J Psychopharmacol. 2020;34(1):3–78. doi:10.1177/0269881119889296
   PubMed Web of Science ®Google Scholar
• Kozma CM, Weiden PJ. Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database. Am Health Drug Benefits. 2009;2(1):31–38.
   PubMedGoogle Scholar
• Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30(2):255–264. doi:10.1093/oxfordjournals.schbul.a007076
   PubMed Web of Science ®Google Scholar
• Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry. 1985;46(11):18–21.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196–201. doi:10.1176/ps.49.2.196
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JMJ, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247. doi:10.1001/archpsyc.56.3.241
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 2013;148(1–3):117–121. doi:10.1016/j.schres.2013.05.016
   PubMed Web of Science ®Google Scholar
• Fitzgerald HM, Shepherd J, Bailey H, Berry M, Wright J, Chen M. Treatment goals in schizophrenia: a real-world survey of patients, psychiatrists, and caregivers in the United States, with an analysis of current treatment (long-acting injectable vs oral antipsychotics) and goal selection. Neuropsychiatr Dis Treat. 2021;17:3215–3228. doi:10.2147/NDT.S330936
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24. doi:10.4088/JCP.15032su1
   PubMed Web of Science ®Google Scholar
• Reus VI, Fochtmann LJ, Bukstein O, et al. The American psychiatric association practice guideline for the pharmacological treatment of patients with alcohol use disorder. American Psychiatric Pub. 2018;175(1):86–90. doi:10.1176/appi.ajp.2017.1750101
   PubMed Web of Science ®Google Scholar
• Group CSC. Expert consensus on long-acting injectable in the treatment of schizophrenia. Chin J Psychiatry. 2020;2:99–100.
   Google Scholar
• Nasser AF, Henderson DC, Fava M, et al. Efficacy, safety, and tolerability of rbp-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016;36(2):130–140. doi:10.1097/JCP.0000000000000479
   PubMed Web of Science ®Google Scholar
• Ravenstijn P, Remmerie B, Savitz A, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2016;56(3):330–339. doi:10.1002/jcph.597
   PubMed Web of Science ®Google Scholar
• Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171. doi:10.2147/PPA.S53795
   PubMed Web of Science ®Google Scholar
• Okoli CTC, Kappi A, Wang T, Makowski A, Cooley AT. The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: a systematic review and meta-analysis. Int J Ment Health Nurs. 2022;31(3):469–535. doi:10.1111/inm.12964
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull. 2007;33(6):1379–1387. doi:10.1093/schbul/sbm033
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842–851. doi:10.1056/NEJMoa1005987
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen Y, Lu W, et al. Attitudes and Willingness to accept long-acting injections for patients with schizophrenia in Beijing: a cross-sectional investigation based on samples from the communities. Front Public Health. 2021;9:770276. doi:10.3389/fpubh.2021.770276
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387–404. doi:10.1016/S2215-0366(21)00039-0
   PubMed Web of Science ®Google Scholar
• Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824–836. doi:10.1016/S0140-6736(21)01997-8
   PubMed Web of Science ®Google Scholar
• Banerjee A. Cross-cultural variance of schizophrenia in symptoms, diagnosis and treatment. Georgetown Univer J Health Sci. 2012;6(2):18–24.
   Google Scholar
• Stauffer VL, Sniadecki JL, Piezer KW, et al. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. BMC Psychiatry. 2010;10(1):1–11. doi:10.1186/1471-244X-10-89
   PubMedGoogle Scholar
• Coppola D, Liu Y, Gopal S, et al. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry. 2012;12(1):1–14. doi:10.1186/1471-244X-12-26
   PubMedGoogle Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–473. doi:10.7326/M18-0850
   PubMed Web of Science ®Google Scholar
• A E, M Z. JBI Reviewer’s Manual; 2017. Available from: https://reviewersmanual.joannabriggs.org/. Accessed September 12, 2023.
   Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study. Neuropsychiatr Dis Treat. 2017;13:2193–2207. doi:10.2147/NDT.S134287
   PubMed Web of Science ®Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population. Neuropsychiatr Dis Treat. 2019;15:587–602. doi:10.2147/NDT.S189668
   PubMed Web of Science ®Google Scholar
• Hanping B, Qianjun Y, Juncheng Z. Paliperidone palmitate in the treatment of 40 college students with schizophrenia (Article in Chinese). J Herald of Medicine. 2015;4:483–486.
   Google Scholar
• Liu CC, Shan JC, Chiang CL, et al. Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia--A 3-year follow-up. J Formos Med Assoc. 2015;114(6):539–545. doi:10.1016/j.jfma.2013.01.004
   PubMed Web of Science ®Google Scholar
• Lin C-H, Chen F-C, Chan H-Y, Hsu -C-C. A comparison of long-acting injectable antipsychotics with oral antipsychotics on time to rehospitalization within 1 year of discharge in elderly patients with schizophrenia. Am J Geriatr Psychiatry. 2020;28(1):23–30. doi:10.1016/j.jagp.2019.08.005
   PubMed Web of Science ®Google Scholar
• Wu CS, Cheng IC, Feng J, Chen CL. Comparison of treatment effectiveness and medical costs for different long-acting injectable antipsychotics in patients with schizophrenia in Taiwan: a nationwide population-based cohort study. Schizophr Res. 2016;173(1–2):37–44. doi:10.1016/j.schres.2016.02.037
   PubMed Web of Science ®Google Scholar
• Chiou CF, Wang BC, Caldwell R, et al. The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia. Neuropsychiatr Dis Treat. 2015;11:1989–1994. doi:10.2147/NDT.S86722
   PubMed Web of Science ®Google Scholar
• Lee D, Lee BC, Choi SH, Kang DH, Jon DI, Jung MH. Effects of paliperidone palmitate on healthcare utilization and costs for patients with schizophrenia: a claim-based mirror-image study in South Korea. Clin Psychopharmacol Neurosci. 2020;18(2):303–310. doi:10.9758/cpn.2020.18.2.303
   PubMed Web of Science ®Google Scholar
• Wu DB, Lee EH, Chung WS, et al. Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations. Psychiatry Res. 2013;210(3):745–750. doi:10.1016/j.psychres.2013.07.012
   PubMed Web of Science ®Google Scholar
• Zhang F, Si T, Chiou CF, et al. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatr Dis Treat. 2015;11:657–668. doi:10.2147/NDT.S77778
   PubMed Web of Science ®Google Scholar
• Misawa F, Okumura Y, Takeuchi Y, Fujii Y, Takeuchi H. Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: analyses based on a spontaneous reporting system database in Japan. Schizophr Res. 2021;231:42–46. doi:10.1016/j.schres.2021.02.016
   PubMed Web of Science ®Google Scholar
• Zhang H, Turkoz I, Zhuo J, Mathews M, Tan W, Feng Y. Paliperidone palmitate improves and maintains functioning in Asia-Pacific patients with Schizophrenia. Adv Ther. 2017;34(11):2503–2517. doi:10.1007/s12325-017-0638-0
   PubMed Web of Science ®Google Scholar
• Hsu HF, Kao CC, Lu T, Ying JC, Lee SY. Differences in the effectiveness of long-acting injection and orally administered antipsychotics in reducing rehospitalization among patients with schizophrenia receiving home care services. J Clin Med. 2019;8(6):823. doi:10.3390/jcm8060823
   PubMed Web of Science ®Google Scholar
• Chan HW, Huang CY, Feng WJ, Yen YC. Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: a retrospective cohort study. Psychiatry Clin Neurosci. 2015;69(8):497–503. doi:10.1111/pcn.12294
   PubMed Web of Science ®Google Scholar
• Li H, Turkoz I, Zhang F. Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study. Neuropsychiatr Dis Treat. 2016;12:15–24. doi:10.2147/NDT.S83651
   PubMed Web of Science ®Google Scholar
• Li H, Li Y, Feng Y, et al. Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study. Neuropsychiatr Dis Treat. 2018;14:1107–1117. doi:10.2147/NDT.S157399
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Liu J, et al. Persistence with and adherence to paliperidone palmitate once-monthly injection for schizophrenia treatment in China and Japan. J Clin Psychiatry. 2021;83(1). doi:10.4088/JCP.20m13850
   Web of Science ®Google Scholar
• Chang HC, Tang CH, Huang ST, McCrone P, Su KP. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan. J Psychiatr Res. 2012;46(6):751–756. doi:10.1016/j.jpsychires.2012.02.019
   PubMed Web of Science ®Google Scholar
• Liu J, Wang Q, Su L, Yang L, Zou L, Bai L. A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China. BMC Psychiatry. 2022;22(1):95. doi:10.1186/s12888-022-03728-2
   PubMed Web of Science ®Google Scholar
• Zhao J, Li L, Shi J, et al. Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study. Neuropsychiatr Dis Treat. 2017;13:2045–2056. doi:10.2147/NDT.S131224
   PubMed Web of Science ®Google Scholar
• Ishigooka J, Nakamura J, Fujii Y, et al. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. 2015;161(2–3):421–428. doi:10.1016/j.schres.2014.12.013
   PubMed Web of Science ®Google Scholar
• Kwon JS, Kim SN, Han J, et al. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. Int Clin Psychopharmacol. 2015;30(6):320–328. doi:10.1097/YIC.0000000000000093
   PubMed Web of Science ®Google Scholar
• Xiao L, Zhao Q, Li AN, et al. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study. Psychopharmacology. 2022;239(1):243–251. doi:10.1007/s00213-021-06044-x
   PubMed Web of Science ®Google Scholar
• Hatano M, Kamei H, Shimato A, Yamada S, Iwata N. Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database. Psychiatry Res. 2020;291:113249. doi:10.1016/j.psychres.2020.113249
   PubMed Web of Science ®Google Scholar
• Qiyi M, Kui C, Jianhong S, Guangya Z, Yong Y, Yingcui H. Predictor of discontinuation with paliperidone palmitate in patients with schizophrenia (Article in Chinese. Chin J Psychiatry. 2016;49(6):373–377.
   Google Scholar
• Xingfang M, Qian W, Jie L, Ludong B. An open-label study on the efficacy of paliperidone palmitate in patients with acute schizophrenia (Article in Chinese). Chin J New Drugs. 2014;23(19):2280–2283.
   Google Scholar
• Takahashi N, Takahashi M, Saito T, et al. Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia. Neuropsychiatr Dis Treat. 2013;9:1889–1898. doi:10.2147/NDT.S54051
   PubMed Web of Science ®Google Scholar
• Lee NY, Kim SH, Cho SJ, et al. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. Int Clin Psychopharmacol. 2014;29(5):279–287. doi:10.1097/YIC.0000000000000030
   PubMed Web of Science ®Google Scholar
• Li N, Feng Y, Lu H, et al. Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics. Neuropsychiatr Dis Treat. 2018;14:825–837. doi:10.2147/NDT.S158353
   PubMed Web of Science ®Google Scholar
• Li N, Zhuo JM, Turkoz I, Mathews M, Feng Y, Tan W. A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics. Expert Opin Pharmacother. 2019;20(16):2033–2039. doi:10.1080/14656566.2019.1650022
   PubMed Web of Science ®Google Scholar
• Ju PC, Chou FH, Lai TJ, et al. Long-acting injectables and risk for rehospitalization among patients with schizophrenia in the home care program in Taiwan. J Clin Psychopharmacol. 2014;34(1):23–29. doi:10.1097/JCP.0b013e3182a6a142
   PubMed Web of Science ®Google Scholar
• Guoxing Q, Jianguang G, Guoqiang T. Clinical controlled study on the effect of risperidone microsphere on schizophrenia (Article in Chinese). Chin Gen Pract. 2013;16(3):308–309.
   Google Scholar
• Huang SS, Lin CH, Lohel W, Yang HY, Chan CH, Lan TH. Antipsychotic formulation and one-year rehospitalization of schizophrenia patients: a population-based cohort study. Psychiatr Serv. 2013;64(12):1259–1262. doi:10.1176/appi.ps.201200506
   PubMed Web of Science ®Google Scholar
• Fang SC, Liao DL, Huang CY, Hsu CC, Cheng SL, Shao YJ. The effectiveness of long-acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia. Hum Psychopharmacol. 2020;35(3):e2729. doi:10.1002/hup.2729
   PubMed Web of Science ®Google Scholar
• Joo SW, Shon SH, Choi G, Koh M, Cho SW, Lee J. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: a nationwide population-based study. Eur Neuropsychopharmacol. 2019;29(9):1051–1060. doi:10.1016/j.euroneuro.2019.07.138
   PubMed Web of Science ®Google Scholar
• Kim SW, Lee YH, Jang JE, et al. Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients. Int Clin Psychopharmacol. 2013;28(2):80–86. doi:10.1097/YIC.0b013e32835d30ae
   PubMed Web of Science ®Google Scholar
• Fan SJ, Lu N, Chang HC, Tang CH, Huang KC. Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in Taiwan. Int Clin Psychopharmacol. 2018;33(4):204–212. doi:10.1097/YIC.0000000000000213
   PubMed Web of Science ®Google Scholar
• Wei T, Fuyin Y, Na W, Jianshe P, Jinliang Z, Wenjie T. A comparative study of paliperidone palmitate injections and risperidone on long-term effects and prognosis for the first-episode schizophrenic patients. Chin J Psychiatry. 2016;49(2):76–80.
   Google Scholar
• Si T, Zhang K, Tang J, et al. Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study. Neuropsychiatr Dis Treat. 2015;11:1483–1492. doi:10.2147/NDT.S81760
   PubMed Web of Science ®Google Scholar
• Si T, Li N, Lu H, et al. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: a post-hoc analysis of a one-year, open-label study stratified by medication adherence. J Psychopharmacol. 2018;32(6):691–701. doi:10.1177/0269881118772449
   PubMed Web of Science ®Google Scholar
• Si T, Zhuo J, Feng Y, Lu H, Hong D, Zhang L. Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1685–1694. doi:10.2147/NDT.S191803
   PubMed Web of Science ®Google Scholar
• Jian W, Li ZX, Wei L, et al. Clinical effect of paliperidone palmitate and risperdal consta in the treatment of patients with schizophrenia. Chin J Clin Pharmacol. 2015;12:1124–1126.
   Google Scholar
• Chen WY, Lin SK. Comparison of subjective experiences and effectiveness of first-generation long-acting injectable antipsychotics and risperidone long-acting injectables in patients with schizophrenia. J Clin Psychopharmacol. 2016;36(5):492–495. doi:10.1097/JCP.0000000000000555
   PubMed Web of Science ®Google Scholar
• Qiuxia X, Jushui S, Shikai W, Xilong J, Weigang G, Xiongkai D. Paliperidone palmitate injection in the treatment of 36 cases of acute schizophrenia (Article in Chinese). Herald Med. 2015;10:1304–1307.
   Google Scholar
• Koshikawa Y, Takekita Y, Kato M, et al. The comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: a 6-month, open-label, randomized controlled pilot trial. Neuropsychobiology. 2016;73(1):35–42. doi:10.1159/000442209
   PubMed Web of Science ®Google Scholar
• Savitz AJ, Xu H, Gopal S, Nuamah I, Mathews M, Soares B. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: a subgroup analysis of data from two large phase 3 randomized, double-blind studies. Braz J Psychiatry. 2019;41(6):499–510. doi:10.1590/1516-4446-2018-0153
   PubMedGoogle Scholar
• Wei Y, Yan VK, Kang W, et al. Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia. JAMA network open. 2022;5(7):e2224163–e2224163. doi:10.1001/jamanetworkopen.2022.24163
   PubMed Web of Science ®Google Scholar
• Fang S-C, Huang C-Y, Shao Y-HJ. Long-term outcomes of early use of long-acting injectable antipsychotics in schizophrenia. J Clin Psychiatry. 2022;83(4):41243. doi:10.4088/JCP.21r14153
   Web of Science ®Google Scholar
• Park S-C, Choi MY, Choi J, et al. Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and meta-analysis. Clin Psychopharmacol Neurosci. 2018;16(4):361–375. doi:10.9758/cpn.2018.16.4.361
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609. doi:10.1176/appi.ajp.2011.10081224
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Alfonsi E, Amodeo G, et al. Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists. Expert Opin Drug Saf. 2016;15(4):449–455. doi:10.1517/14740338.2016.1155553
   PubMed Web of Science ®Google Scholar
• Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatr Dis Treat. 2019;15:183–198. doi:10.2147/NDT.S189245
   PubMed Web of Science ®Google Scholar
• Shah A, Xie L, Kariburyo F, Zhang Q, Gore M. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. Adv Ther. 2018;35(11):1994–2014. doi:10.1007/s12325-018-0786-x
   PubMed Web of Science ®Google Scholar
• Suzuki H, Inoue Y, Gen K. A study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia. Ther Adv Psychopharmacol. 2012;2(6):227–234. doi:10.1177/2045125312457585
   PubMedGoogle Scholar
• Altamura AC, Aguglia E, Bassi M, et al. Rethinking the role of long-acting atypical antipsychotics in the community setting. Int Clin Psychopharmacol. 2012;27(6):336–349. doi:10.1097/YIC.0b013e328357727a
   PubMed Web of Science ®Google Scholar
• Latorre V, Papazacharias A, Lorusso M, et al. Improving the “real life” management of schizophrenia spectrum disorders by LAI antipsychotics: a one-year mirror-image retrospective study in community mental health services. PLoS One. 2020;15(3):e0230051. doi:10.1371/journal.pone.0230051
   PubMed Web of Science ®Google Scholar